IP Library › Granted Patent US 11,464,848
Granted Patent B2
US 11,464,848 · App. 16/494,103 · Granted Oct 11, 2022

Respiratory syncytial virus vaccine

Inventors: Giuseppe Ciaramella (Sudbury, MA); Kapil Bahl (Medford, MA); Amy Espeseth (Chalfont, PA); Dai Wang (Blue Bell, PA); Andrew J. Bett (Lansdale, PA)
Assignee: ModernaTX, Inc.
A61K39/12A61K9/0019A61K9/5123A61K9/5146A61P31/14C07K16/1027C12N7/00A61K2039/53A61K2039/54A61K2039/545A61K2039/70C07K2317/10C07K2317/76C12N2760/18533
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,464,848
App. No.
16/494,103
Granted
Oct 11, 2022
Kind
B2
Abstract

The disclosure describes respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

Claims (17)

1. A composition comprising a ribonucleic acid (RNA) polynucleotide having an open reading frame encoding a respiratory syncytial virus (RSV) antigenic polypeptide and a lipid nanoparticle comprising 10-20 mol % neutral lipid, 35-45 mol % cholesterol, 1-5% PEG-modified lipid, and 40-50 mol % ionizable cationic lipid, wherein the ionizable cationic lipid comprises Compound 25:

2. The composition of claim 1 , wherein the antigenic polypeptide is glycoprotein G.

3. The composition of claim 1 , wherein the antigenic polypeptide is glycoprotein F.

4. The composition of claim 1 , further comprising an adjuvant.

5. The composition of claim 1 , further comprising a pharmaceutically acceptable carrier.

6. The composition of claim 1 , wherein the open reading frame is codon-optimized.

7. The composition of claim 1 , wherein the vaccine is multivalent.

8. The composition of claim 1 , wherein the RNA polynucleotide encodes at least 2 antigenic polypeptides.

9. The composition of claim 1 , wherein the RNA polynucleotide comprises a chemical modification.

10. The composition of claim 9 , wherein the chemical modification is selected from the group consisting of pseudouridine, 1-methylpseudouridine, 1-ethylpseudouridine, 2-thiouridine, 4′-thiouridine, 5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine and 2′-O-methyl uridine.

11. The composition of claim 1 , wherein the nanoparticle has a mean diameter of 50-200 nm.

12. The composition of claim 1 , wherein the sterol is a cholesterol.

13. The composition of claim 1 , wherein the nanoparticle has a polydispersity value of less than 0.4.

14. The composition of claim 1 , wherein the nanoparticle has a net neutral charge at a neutral pH value.

15. A method of administering to a subject the RSV composition of claim 1 .

16. The composition of claim 3 , wherein the glycoprotein F is a stabilized prefusion form of glycoprotein F.

17. The composition of claim 10 , wherein the chemical modification is 1-methylpseudouridine.

Assignments (4)
SECURITY INTEREST Recorded Nov 19, 2025
From: MODERNATX, INC.
To: ARES CAPITAL CORPORATION, AS AGENT
Reel/Frame 073634/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2020
From: CIARAMELLA, GIUSEPPE; BAHL, KAPIL
To: MODERNATX, INC.
Reel/Frame 051748/0446 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2020
From: ESPESETH, AMY; WANG, DAI; BETT, ANDREW J.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 051748/0493 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2020
From: MERCK SHARP & DOHME CORP.
To: MODERNATX, INC.
Reel/Frame 051748/0530 →